Navin Molecular to Invest $35 Mn to Expand GMP Manufacturing Plant

This new plant aims to nearly double the current manufacturing capacity, supporting both existing commercial-scale projects and future demand.

Navin Molecular, a contract development and manufacturing organization (CDMO) based in Madhya Pradesh, has announced an investment of INR 288 Cr (approximately US$35 million) to expand its GMP manufacturing capabilities.

The expansion project will see the construction of a 9,000sq m facility in Dewas, India. The construction project is scheduled to be completed by the end of 2025 and is expected to create up to 100 new jobs.

The new facility will nearly double overall capacity at the site to 420 cubic meters, and will support existing commercial-scale projects, as well as meeting future demands as the company continues to expand its global customer base.

Sharing thoughts, Rajendra Kumar Sahu, CEO of Navin Molecular, said, “As our business expands, we are progressing numerous projects to increase in scale towards commercial manufacturing, as well as investing in new, more advanced and niche technologies that we had previously identified as growth opportunities.”

Additionally, the plant will incorporate a high level of automated control, featuring a distributed control system (DCS) to maximize efficiency and minimize risks to employees and the environment.

“Combined, this additional capacity and broadened technology platform will satisfy these growing volumes and build for the future, enabling us to capitalize on both horizontal and vertical market openings,” Sahu added.

In addition to increasing manufacturing capacity, the expansion will enhance the site's existing 21 CFR-compliant QC laboratory, which performs in-process testing and final product release. A new process safety laboratory and a dedicated zero liquid discharge (ZLD) effluent treatment plant will also be constructed.

These additions will comply with India’s green building standards, using modern materials, equipment, and design technologies, including renewable energy generation and solvent containment.

“The new facility has been designed with sustainability at its core to minimize its environmental impact while allowing us to continue to provide the highest quality, cost-effective manufacturing solutions for our customers,” added Sahu.

Navin Molecular, launched in 2023 as the CDMO division of Navin Fluorine, supports global pharmaceutical innovators. The company’s 47-acre site in Dewas offers comprehensive services from process research and development to commercial manufacturing of a wide range of regulatory starting materials and API intermediates.